Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(MDRX)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
19.06 USD   +0.85%
11/30Sphere's TrustCommerce® Healthcare Payments Platform Now Integrated with Veradigm® Practice Management
PR
11/22Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association
BU
11/18JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maintains Underweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Allscripts to Sell the Net Assets of Its Hospitals & Large Physician Practices Business Segment to Constellation Software

03/02/2022 | 05:01pm EST

Allscripts Healthcare Solutions (NASDAQ: MDRX) (“Allscripts”) announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris Computer Corporation (“Harris”), to sell Harris the net assets of Allscripts Hospitals and Large Physician Practices business segment. The Hospitals and Large Physician Practices business segment includes the Sunrise™, Paragon®, Allscripts TouchWorks®, Allscripts® Opal, STAR™, HealthQuest™ and dbMotion™ solutions. The assets of Allscripts Veradigm business segment are not included in this transaction and will continue to be owned by Allscripts going forward.

“The medical industry we faithfully serve has gone through tremendous change and the needs of the customers in our different business segments continue to evolve in different ways. We think this transaction maximizes focus as well as future opportunity for our clients, our more than 7,500 associates and our shareholders,” said Paul M. Black, Allscripts Chief Executive Officer. “Harris has demonstrated excellence in software development, customer satisfaction and worldwide growth in healthcare. We are pleased that our solutions will be a key strategic component of Harris’ plans to become leaders in digital health. As the cornerstone of the Harris portfolio, we are proud that our customers will continue to benefit from a true platform of health.”

The purchase price consideration is up to $700 million cash, consisting of a fixed price of $670 million paid at closing, plus contingent consideration of up to $30 million based on performance of the business during the two years following transaction closing. The transaction is subject to regulatory approval and customary closing conditions, and is expected to close during the second quarter.

“We have been watching and admiring the hospitals and large physician practices franchise for many years,” said Harris CEO Jeff Bender. “We believe that we are the perfect forever home for the many talented employees and loyal customers that are the backbone of the franchise. We are excited to begin the next chapter in our Harris story, continuing to serve those who serve us in the communities where we live, by partnering with healthcare professionals to deliver care that improves lives.”

William Blair & Company served as advisor and provided a fairness opinion on the transaction to Allscripts Board of Directors. Additional details regarding the sale will be made available in a Form 8-K to be filed by Allscripts with the Securities and Exchange Commission.

Conference Call

Allscripts will conduct a conference call tomorrow, Thursday, March 3, 2022, at 8:30AM Eastern Time to discuss further details of the transaction and provide an updated outlook for 2022. Participants may access the conference call via webcast at http://investor.allscripts.com. Participants also may access the conference call by dialing +1 (877) 269-7756 or +1 (201) 689-7817 (international) and requesting Conference ID # 13727538.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and The Allscripts Blog.

About Constellation Software Inc.

Constellation's common shares are listed on the Toronto Stock Exchange under the symbol "CSU". Constellation acquires, manages and builds vertical market software businesses.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to the timing or ultimate completion of the sale of the Hospitals and Large Physician Practices business, as the transaction is subject to certain closing conditions as noted herein, our use of the proceeds from the contemplated sale of our Hospital and Large Physician Practices business, and potential benefits to our shareholders. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.


© Business Wire 2022
All news about ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
11/30Sphere's TrustCommerce® Healthcare Payments Platform Now Integrated with Veradigm® Prac..
PR
11/22Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Poin..
BU
11/18JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maint..
MT
11/14Insider Sell: Allscripts Healthcare Solutions
MT
11/10Allscripts - Veradigm EHR Achieves 2015 ONC Health IT Update Certification
AQ
11/09Goldman Sachs Upgrades Allscripts Healthcare Solutions to Buy From Neutral, Adjusts Pri..
MT
11/09Veradigm EHR Achieves 2015 ONC Health IT Update Certification
BU
11/07ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Management's Discussion and Analysis of Financia..
AQ
11/07Tranche Update on Allscripts Healthcare Solutions, Inc.'s Equity Buyback Plan announced..
CI
11/07Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $21 From $20, Mai..
MT
More news
Analyst Recommendations on ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
More recommendations
Financials (USD)
Sales 2022 615 M - -
Net income 2022 1,69 M - -
Net cash 2022 300 M - -
P/E ratio 2022 -318x
Yield 2022 -
Capitalization 2 082 M 2 082 M -
EV / Sales 2022 2,90x
EV / Sales 2023 2,74x
Nbr of Employees 8 000
Free-Float 38,1%
Chart ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Duration : Period :
Allscripts Healthcare Solutions, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 19,06 $
Average target price 22,00 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Richard J. Poulton Chief Executive Officer & Director
Thomas Langan President
Leah Jones Vice President-Finance & Sales Support
Joseph R. Rostock Chief Technology Officer & SVP-Product Engineering
Tejal Vakharia Chief Compliance Counsel & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.3.31%2 082
VEEVA SYSTEMS INC.-31.54%27 159
PRO MEDICUS LIMITED-2.35%4 319
SECTRA AB (PUBL)-12.29%3 258
EVOLENT HEALTH, INC.3.29%2 848
OMNICELL, INC.-71.82%2 270